Search Within

Lauren Rhea Schaff

  1. "American Society of Hematology"
Formats
  1. Meeting Abstract (5)
  2. Review (1)
Groups
  1. GSK Faculty (3)
  2. Human Oncology and Pathogenesis Program (3)
  3. Tow Center for Developmental Oncology (TCDO) (3)
  4. Biostatistics Service (2)
  5. Epidemiology and Biostatistics (2)
  6. Nursing (2)

More Groups

People
  1. Christian Grommes (6)
  2. Ingo Mellinghoff (3)
  3. Anna Piotrowski (2)
  4. Craig Nolan (2)
  5. Elena Pentsova (2)
  6. Igor Gavrilovic (2)

More People

Years
  1. 2022 (3)
  2. 2020 (1)
  3. 2019 (2)
Publications
  1. Blood (6)
Publishers
  1. American Society of Hematology (6)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Piotrowski, A.; Pentsova, E.; Gavrilovic, I.; Stone, J. B.; Lin, A.; Wongchai, V.; Madzsar, J. T.; Malani, R.; Nolan, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Initial treatment response is prognostic and predictive of relapse patterns: Outcomes of >500 patients treated for primary CNS lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; Cederquist, G. Y.; Vachha, B.; Schaff, L.; Hajj, C.; Hubbeling, H.; Zhang, Z.; White, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Primary central nervous system lymphoma
    Review

    Schaff, L. R.; Grommes, C.
    Blood (2022)

    Fulltext@MSK | Save
  • Phase Ib trial with dose expansion of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in patients with refractory/recurrent primary central nervous system lymphoma (PCNSL) and refractory/recurrent secondary central nervous system lymphoma (SCNSL)
    Meeting Abstract

    Grommes, C.; Piotrowski, A.; Pentsova, E.; Nolan, C.; Francis, J.; DeAngelis, L.; Schaff, L.; Mellinghoff, I. K.
    Blood (2020)

    Fulltext@MSK | Save
  • Increased number of high dose methotrexate cycles and the addition of rituximab is associated with better outcomes in a large primary CNSL cohort
    Meeting Abstract

    Yerram, P.; Reiss, S. N.; Modelevsky, L.; Schaff, L.; Reiner, A.; Panageas, K.; Grommes, C.
    Blood (2019)

    Fulltext@MSK | Save
  • Phase Ib of copanlisib in combination with ibrutinib in recurrent/refractory primary CNS lymphoma (PCNSL)
    Meeting Abstract

    Grommes, C.; Gavrilovic, I.; Miller, A. M.; Stone, J. B.; Kaley, T.; Madzsar, J. T.; Schumpp, A.; Butler, B. T.; Schaff, L.; Mellinghoff, I. K.
    Blood (2019)

    Fulltext@MSK | Save